Egalet CEO Bob Radie Tells Benzinga Mgmt Continues to Evaluate Whether or Not Added Clinical Work on ARYMO to Achieve Abuse-Deterrent Label is Necessary, Says Oral Data Generated May Be Sufficient
Paul Quintaro